Long-term follow-up with a clinical decision support system based on laboratory reports to manage patients with biochemical recurrence after radical prostatectomy

Skove, 2017, Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence, Urology, 108, 129, 10.1016/j.urology.2017.07.009 Tourinho-Barbosa, 2018, Biochemical recurrence after radical prostatectomy: what does it mean?, International braz j urol : official journal of the Brazilian Society of, Urology, 44, 14 McCormick, 2019, Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies, Indian J. Urol., 35, 6, 10.4103/iju.IJU_355_18 E. Schaeffer, S. Srinivas, E.S. Antonarakis, A.J. Armstrong, J.E. Bekelman, H. Cheng, A.V. D'Amico, B.J. Davis, N. Desai, T. Dorff, J.A. Eastham, T.A. Farrington, X. Gao, E.M. Horwitz, J.E. Ippolito, M.R. Kuettel, J.M. Lang, R. McKay, J. McKenney, G. Netto, D.F. Penson, J.M. Pow-Sang, R. Reiter, S. Richey, M. Roach Iii, S. Rosenfeld, A. Shabsigh, D.E. Spratt, B.A. Teply, J. Tward, D.A. Shead, D.A. Freedman-Cass, NCCN Guidelines Insights: Prostate Cancer, Version 1.2021, Journal of the National Comprehensive Cancer Network : JNCCN 19(2) (2021) 134-143. Ferraro, 2021, Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions, Clin. Chem., 67, 543, 10.1093/clinchem/hvaa268 Tilki, 2015, Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review, J. Urol., 193, 1525, 10.1016/j.juro.2014.10.087 La Casta, 2021, Hacia un laboratorio líder, Revista de Medicina de, Laboratorio, 2, 1 Gruson, 2021, Big Data, artificial intelligence and laboratory medicine: time for integration, Adv. Lab. Med., 2, 1 World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects, Jama 310(20) (2013) 2191-4. European Medicine Agency. Guideline for Good Clinical Practice:. https://www.ema.europa.eu/en/ich-e6-r2-good-clinical-practice-scientific-guideline. Cookson, 2007, J. Urol., 177, 540, 10.1016/j.juro.2006.10.097 Van den Broeck, 2020, Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations, Eur. Urol. Focus, 6, 231, 10.1016/j.euf.2019.06.004 Trock, 2008, Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy, JAMA, 299, 2760, 10.1001/jama.299.23.2760 Arlen, 2008, Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time, J. Urol., 179, 2181, 10.1016/j.juro.2008.01.099 Teeter, 2018, Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group, J. Urol., 199, 713, 10.1016/j.juro.2017.08.107 Koulikov, 2014, Low detectable prostate specific antigen after radical prostatectomy–treat or watch?, J. Urol., 192, 1390, 10.1016/j.juro.2014.05.088 Greenberg, 2021, Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen, J. Urol., 206, 706, 10.1097/JU.0000000000001793 Shen, 2005, Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy, J. Urol., 173, 777, 10.1097/01.ju.0000153619.33446.60 Taylor, 2006, The relationship of ultrasensitive measurements of prostate-specific antigen levels to prostate cancer recurrence after radical prostatectomy, BJU Int., 98, 540, 10.1111/j.1464-410X.2006.06294.x Filella, 2019, Prostate cancer screening: guidelines review and laboratory issues, Clin. Chem. Lab. Med., 57, 1474, 10.1515/cclm-2018-1252